Cancer BiologyMolecular Therapy OncologyPeer-reviewed
Targeting MDM2 homodimer and heterodimer disruption with DRx-098D in TP53 wild-type and mutant cancer cells
Sean F Cooke, Thomas A. Wright, Gillian Lappin…·Connor M. Blair
This study shows DRx-098D, a peptide disrupting MDM2 dimerisation, effectively inhibits cancer cell growth in TP53 wild-type and mutant cell lines, outperforming Idasanutlin in TP53 null cells.
2 citations